PULMONARY FUNCTION, ANTIOXIDANT ENZYMES, AND MELATONIN LEVELS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE DURING STABLE AND EXACERBATION PERIODS
Main Article Content
Keywords
Pulmonary function, Antioxidant Enzymes, Chronic Obstructive Pulmonary Disease, Oxidant-antioxidant, Exacerbation, Stable periods
Abstract
Background: In the development and progression of bronchial asthma and chronic obstructive pulmonary disease important role is played by an imbalance between oxidative stress and antioxidative capacity. The purpose of the study was to evaluate the BA and COPD systemic oxidant-antioxidant status during the exacerbation and the stable periods.
Methodology: This study was conducted at DHQ Hospital, Charsadda. ‘The patients with BA and COPD’ were 40, which were divided into 20 with BA and 20 with COPD. An investigation was carried out i-e “levels of malondialdehyde (MDA), activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GRd), and catalase (CAT) in erythrocytes and serum melatonin concentrations” ‘during the exacerbation’ and the stable periods. Additionally, the respiratory functions, blood gases, and Blood counts were investigated.
Results: Bronchial asthma during an exacerbation period the % of eosinophils was higher significantly than in the stable period despite the declines in, GRd, GSH-Px, MDA, melatonin levels, white blood cell count, and CAT levels. We evaluate that increased during the stable period with, FVC/L, BA FEV1/L pO2, PEF/L/s, levels. GSH-Px, GRd, melatonin, pH, and pO2 levels were lower in the exacerbation period than in the stable period while MDA and SOD values were higher in the exacerbation period than in the stable period. The change between the exacerbation and the stable period with COPD, blood counts, and respiratory function tests did not change significantly.
Conclusion: (BA or COPD) may be linked with elevated levels of oxidative stress, because of increased levels of oxidative stress in the exacerbation period with BA and COPD although the levels decreased antioxidant enzymes and melatonin.
References
2. Liu Y, Li L, Feng J, Wan B, Tu Q, Cai W, et al. Modulation of chronic obstructive pulmonary disease progression by antioxidant metabolites from Pediococcus pentosaceus: enhancing gut probiotics abundance and the tryptophan-melatonin pathway. Gut Microbes. 2024;16(1):2320283.
3. Hanna M, Elnassag SS, Mohamed DH, Elbaset MA, Shaker O, Khowailed EA, et al. Melatonin and mesenchymal stem cells co-administration alleviates chronic obstructive pulmonary disease via modulation of angiogenesis at the vascular-alveolar unit. Pflügers Archiv-European Journal of Physiology. 2024;476(7):1155-68.
4. Janciauskiene S. The beneficial effects of antioxidants in health and diseases. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2020;7(3):182.
5. Xu M-M, Kang J-Y, Wang Q-Y, Zuo X, Tan Y-Y, Wei Y-Y, et al. Melatonin improves influenza virus infection-induced acute exacerbation of COPD by suppressing macrophage M1 polarization and apoptosis. Respiratory Research. 2024;25(1):186.
6. Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting aging pathways in chronic obstructive pulmonary disease. International journal of molecular sciences. 2020;21(18):6924.
7. De Luca SN, Vlahos R. Targeting accelerated pulmonary ageing to treat chronic obstructive pulmonary disease‐induced neuropathological comorbidities. British Journal of Pharmacology. 2024;181(1):3-20.
8. Mazzoccoli G, Kvetnoy I, Mironova E, Yablonskiy P, Sokolovich E, Krylova J, et al. The melatonergic pathway and its interactions in modulating respiratory system disorders. Biomedicine & Pharmacotherapy. 2021;137:111397.
9. Zilli Vieira CL, Koutrakis P, Liu M, Gottlieb DJ, Garshick E. Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD. Respiratory Research. 2023;24(1):91.
10. Al-Azzawi MA, AboZaid MM, Ibrahem RAL, Sakr MA. Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial. Heliyon. 2020;6(8).
11. Zhang X-Y, Li W, Zhang J-R, Li C-Y, Zhang J, Lv X-J. Roles of sirtuin family members in chronic obstructive pulmonary disease. Respiratory Research. 2022;23(1):66.
12. Paudel KR, Jha SK, Allam VSRR, Prasher P, Gupta PK, Bhattacharjee R, et al. Recent advances in chronotherapy targeting respiratory diseases. Pharmaceutics. 2021;13(12):2008.
13. Sierra-Vargas MP, Montero-Vargas JM, Debray-García Y, Vizuet-de-Rueda JC, Loaeza-Román A, Terán LM. Oxidative stress and air pollution: its impact on chronic respiratory diseases. International Journal of Molecular Sciences. 2023;24(1):853.
14. Yeap JW, Ali IAH, Ibrahim B, Tan ML. Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets. Pulmonary Pharmacology & Therapeutics. 2023;81:102218.
15. De Araujo RP. Defining Microbial and Metabolite Markers for Exacerbation in Chronic Obstructive Pulmonary Disease (COPD): Aberystwyth University; 2020.
16. Albano GD, Gagliardo RP, Montalbano AM, Profita M. Overview of the mechanisms of oxidative stress: impact in inflammation of the airway diseases. Antioxidants. 2022;11(11):2237.
17. Mahalanobish S, Dutta S, Sil PC. Chronic Obstructive Pulmonary Disease: Molecular Basis of Pathogenesis and Targeted Therapeutic Approaches. Targeting Cellular Signalling Pathways in Lung Diseases. 2021:163-90.
18. Akata K, van Eeden SF. Lung macrophage functional properties in chronic obstructive pulmonary disease. International journal of molecular sciences. 2020;21(3):853.
19. Yu S, Wang X, Zhang R, Chen R, Ma L. A review on the potential risks and mechanisms of heavy metal exposure to Chronic Obstructive Pulmonary Disease. Biochemical and Biophysical Research Communications. 2023:149124.
20. Çetin AÇ, Tunçok Y, Ecevit MC. Melatonin and allergic rhinitis. Journal of Basic and Clinical Health Sciences. 2020;4(1):1-6.